Clinical evolution of COVID-19 patients with hypertension and/or diabetes in the intensive care units: a systematic review





We aimed to evaluate the association of hypertension and diabetes with the severity prognosis of COVID-19 in ICU hospitalization by analyzing significant differences in epidemiological, clinical and laboratory aspects when compared with non-diabetic and non-hypertensive patients. This review was conducted according to PRISMA, registered on PROSPERO, guided for 4 independent researchers, we used 5 different database and Newcastle-Ottawa scale was the bias analysis applied. A total of 26 articles were included in this review. Diabetics patients admitted to the ICU were older than non-diabetics, about 10 years. Males were associated with a higher chance of death compared to females. Patients with newly diagnosed diabetes and poorly controlled HBA1C had a higher risk of death compared to long-term and controlled patients. Diabetic patients presented evidence that this population tends to have more symptoms in the lower respiratory tract than upper respiratory tract. Procalcitonin levels and CRP proved to be determinant for the patient’s evolution. Hypertensive and diabetics patients who died presented higher d-dimer levels, troponin and NT-proBNP on ICU admission in comparison to patients who survived. Creatinine was higher and this was a marker of severity as it was associated with death. Gender plays an important role in mortality, also advanced age. Diabetes is an independent risk factor for mortality of COVID-19 and mortality, but hypertension is not. We conclude that hypertension and diabetes were significantly associated with COVID-19 patient’s admission to the ICU.


Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus disease 2019 case surveillance — united states, january 22–may 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:759–65.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA 2020;323:1239.

Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020:m1966. https://doi:10.1136/bmj.m1966.

Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in wuhan, china. JAMA 2020;323:1061. https://doi:10.1001/jama.2020.1585.

Bienvenu LA, Noonan J, Wang X, Peter K. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. Cardiovascular Research 2020;116:2197–206.

Liu J. Impact of diabetes mellitus on pneumonia mortality in a senior population: results from the NHANES III follow-up study. J Geriatr Cardiol 2013;10:267–71.

PRISMA-P Group, Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, et al. Preferred reporting items for systematic review and meta-analysis protocols (Prisma-p) 2015 statement. Syst Rev 2015;4:1.

Ottawa hospital research institute n.d. (accessed October 16, 2022).

Lei M, Lin K, Pi Y, Huang X, Fan L, Huang J, et al. Clinical features and risk factors of icu admission for covid-19 patients with diabetes. Journal of Diabetes Research 2020;2020:1–10.

Elemam NM, Hannawi H, Salmi IA, Naeem KB, Alokaily F, Hannawi S. Diabetes mellitus as a comorbidity in COVID-19 infection in the United Arab Emirates. SMJ 2021;42:170–80.

Alshukry A, Bu Abbas M, Ali Y, Alahmad B, Al-Shammari AA, Alhamar G, et al. Clinical characteristics and outcomes of COVID-19 patients with diabetes mellitus in Kuwait. Heliyon 2021;7:e06706.

Fadini GP, Morieri ML, Boscari F, Fioretto P, Maran A, Busetto L, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Research and Clinical Practice 2020;168:108374.

Sonmez A, Demirci I, Haymana C, Tasci I, Dagdelen S, Salman S, et al. Clinical characteristics and outcomes of COVID ‐19 in patients with type 2 diabetes in Turkey : A nationwide study (turcovidia). Journal of Diabetes 2021;13:585–95.

Makati Medical Center, Makati City, Philippines, Sarigumba M, Aragon J, Kanapi MaP. Baseline glycemic status and outcome of persons with type 2 diabetes with covid-19 infections: a single-center retrospective study. JAFES 2021;36:45–9.

Li Y, Han X, Alwalid O, Cui Y, Cao Y, Liu J, et al. Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study. Diabetes Research and Clinical Practice 2020;166:108299.

Halvatsiotis P, Kotanidou A, Tzannis K, Jahaj E, Magira E, Theodorakopoulou M, et al. Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesity. Diabetes Research and Clinical Practice 2020;166:108331.

Wang T, Tang R, Ruan H, Chen R, Zhang Z, Sang L, et al. Predictors of fatal outcomes among hospitalized COVID‐19 patients with pre‐existing hypertension in China. Clin Respir J 2021;15:915–24.

Shaghee F, Nafakhi H, Al-Buthabhak K, Alareedh M, Nafakhi A, Kasim S. Blood parameters, symptoms at presentation and adverse in-hospital outcomes of COVID-19 pneumonia in patients with hypertension. Arterial Hypertension 2021;25:7–14.

Guo T, Shen Q, Ouyang X, Guo W, Li J, He W, et al. Clinical Findings in Diabetes Mellitus Patients with COVID-19. Journal of Diabetes Research 2021;2021:1–7.

Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID ‐19. Diabetes Obes Metab 2020;22:1897–906.

Izzi-Engbeaya C, Distaso W, Amin A, Yang W, Idowu O, Kenkre JS, et al. Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals. BMJ Open Diab Res Care 2021;9:e001858.

Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diab Res Care 2020;8:e001343.

Mithal A, Jevalikar G, Sharma R, Singh A, Farooqui KJ, Mahendru S, et al. High prevalence of diabetes and other comorbidities in hospitalized patients with COVID-19 in Delhi, India, and their association with outcomes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2021;15:169–75.

Lu X, Cui Z, Pan F, Li L, Li L, Liang B, et al. Glycemic status affects the severity of coronavirus disease 2019 in patients with diabetes mellitus: an observational study of CT radiological manifestations using an artificial intelligence algorithm. Acta Diabetol 2021;58:575–86.

Shrestha E, Charkviani M, Musurakis C, Kansakar AR, Devkota A, Banjade R, et al. Type 2 diabetes is associated with increased risk of critical respiratory illness in patients COVID-19 in a community hospital. Obesity Medicine 2021;22:100316.

Pérez-Cruz E, Castañón-González JA, Ortiz-Gutiérrez S, Garduño-López J, Luna-Camacho Y. Impact of obesity and diabetes mellitus in critically ill patients with SARS-CoV-2. Obesity Research & Clinical Practice 2021;15:402–5.

Estedlal A, Jeddi M, Heydari ST, Jahromi MG, Dabbaghmanesh MH. Impacts of diabetes mellitus on clinical and para-clinical parameters among COVID-19 patients. J Diabetes Metab Disord 2021;20:1211–9.

Charoenngam N, Alexanian SM, Apovian CM, Holick MF. Association between Hyperglycemia at Hospital Presentation and Hospital Outcomes in COVID-19 Patients with and without Type 2 Diabetes: A Retrospective Cohort Study of Hospitalized Inner-City COVID-19 Patients. Nutrients 2021;13:2199.

Ran J, Song Y, Zhuang Z, Han L, Zhao S, Cao P, et al. Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. Hypertens Res 2020;43:1267–76.

Wang F, Yang Y, Dong K, Yan Y, Zhang S, Ren H, et al. Clinical Characteristics of 28 Patients with Diabetes and COVID-19 in Wuhan, China. Endocrine Practice 2020;26:668–74.

Liu Z, Bai X, Han X, Jiang W, Qiu L, Chen S, et al. The association of diabetes and the prognosis of COVID-19 patients: A retrospective study. Diabetes Research and Clinical Practice 2020;169:108386.

Clinical characteristics and outcomes in coronavirus disease 2019 (COVID-19) patients with and without hypertension: a retrospective study. Reviews in Cardiovascular Medicine 2020;21:615.

Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert Review of Hematology 2020;13:1265–75.

Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. Journal of Hepatology 2020;73:1231–40.

Prattichizzo F, Sabbatinelli J, de Candia P, Olivieri F, Ceriello A. Tackling the pillars of ageing to fight COVID-19. The Lancet Healthy Longevity 2021;2:e191.

Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst 2020;21:147032032092689.

Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res 2020;126:1671–81.

Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol 2020;5:825.

Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerging Microbes & Infections 2020;9:757–60.

Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol 2020;73:1231–40.

Jing Liang J, Liu J, Chen Y, Ye B, Li N, Wang X, et al. Characteristics of laboratory findings of COVID-19 patients with comorbid diabetes mellitus. Diabetes Research and Clinical Practice 2020;167:108351.

Watson RA, Pride NB, Thomas EL, Fitzpatrick J, Durighel G, McCarthy J, et al. Reduction of total lung capacity in obese men: comparison of total intrathoracic and gas volumes. Journal of Applied Physiology 2010;108:1605–12.

Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020;382:2441–8.

Nardo AD, Schneeweiss‐Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID‐19. Liver Int 2021;41:20–32.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020;395:1054–62.

Wu J, Zhang J, Sun X, Wang L, Xu Y, Zhang Y, et al. Influence of diabetes mellitus on the severity and fatality of SARS‐CoV‐2 (COVID‐19) infection. Diabetes Obes Metab 2020;22:1907–14.

Shang J, Wang Q, Zhang H, Wang X, Wan J, Yan Y, et al. The Relationship Between Diabetes Mellitus and COVID-19 Prognosis: A Retrospective Cohort Study in Wuhan, China. The American Journal of Medicine 2021;134:e6–14.

Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine & Growth Factor Reviews 2020;53:33–7.

Gu SX, Tyagi T, Jain K, et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2021;18(3):194-209.

Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people hospitalized with diabetes mellitus: English record-linkage studies. Diabet Med 2013;30:1412–9.

Domingueti CP, Dusse LMS, Carvalho M das G, de Sousa LP, Gomes KB, Fernandes AP. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. Journal of Diabetes and Its Complications 2016;30:738–45.

Davis TME, Coleman RL, Holman RR. Prognostic Significance of Silent Myocardial Infarction in Newly Diagnosed Type 2 Diabetes Mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79. Circulation 2013;127:980–7.

Abu-Farha M, Al-Mulla F, Thanaraj TA, Kavalakatt S, Ali H, Abdul Ghani M, et al. Impact of Diabetes in Patients Diagnosed With COVID-19. Front Immunol 2020;11:576818.

Opal SM, Girard TD, Ely EW. The Immunopathogenesis of Sepsis in Elderly Patients. Clinical Infectious Diseases 2005;41:S504–12.

Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health 2020;8:152.



Creative Commons License

Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2023 Revista de Ensino, Ciência e Inovação em Saúde